Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company focused on allergic and immunologic diseases, has granted stock options to three new employees under its 2022 Inducement Stock Incentive Plan. The options, totaling 180,000 shares, were issued on September 3, 2024, with an exercise price of $11.46 per share, matching the closing price on the grant date.
These options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. The grants comply with Nasdaq Listing Rule 5635(c)(4) for inducement material to new employees. This plan is exclusively used for equity awards to individuals not previously employed by Astria.
Astria Therapeutics (Nasdaq: ATXS), un'azienda biofarmaceutica focalizzata su malattie allergiche e immunologiche, ha concesso opzioni su azioni a tre nuovi dipendenti ai sensi del suo Piano di Incentivazione Azionaria 2022. Le opzioni, per un totale di 180.000 azioni, sono state emesse il 3 settembre 2024, con un prezzo di esercizio di 11,46 dollari per azione, corrispondente al prezzo di chiusura nella data di concessione.
Queste opzioni matureranno in quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi 36 mesi. Le concessioni sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) per incentivi materiali ai nuovi dipendenti. Questo piano è utilizzato esclusivamente per premi azionari a individui non precedentemente impiegati da Astria.
Astria Therapeutics (Nasdaq: ATXS), una compañía biofarmacéutica centrada en enfermedades alérgicas e inmunológicas, ha otorgado opciones sobre acciones a tres nuevos empleados bajo su Plan de Incentivos de Acciones por Inducción 2022. Las opciones, que suman un total de 180,000 acciones, fueron emitidas el 3 de septiembre de 2024, con un precio de ejercicio de $11.46 por acción, que coincide con el precio de cierre en la fecha de concesión.
Estas opciones se consolidarán en cuatro años, con el 25% consolidándose después de un año y el resto consolidándose mensualmente durante los siguientes 36 meses. Las concesiones cumplen con la Regla de Cotización Nasdaq 5635(c)(4) para incentivos materiales a nuevos empleados. Este plan se utiliza exclusivamente para otorgar premios de equidad a individuos que no han estado empleados anteriormente por Astria.
Astria Therapeutics (Nasdaq: ATXS)는 알레르기 및 면역 질환에 중점을 둔 생물 제약 회사로, 2022 유도 주식 인센티브 계획에 따라 세 명의 새로운 직원에게 주식 옵션을 부여했습니다. 총 180,000주의 옵션은 2024년 9월 3일에 발행되었으며, 발행일의 종가와 일치하는 $11.46의 행사 가격이 책정되었습니다.
이 옵션은 4년 동안 점진적으로 부여되며, 1년 후 25%가 부여되고 나머지는 다음 36개월 동안 매월 부여됩니다. 이 부여는 새로운 직원에게 제공되는 유도 보상에 대한 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다. 이 계획은 Astria에 이전에 고용된 적이 없는 개인에게만 주식 보상을 제공하는 데 독점적으로 사용됩니다.
Astria Therapeutics (Nasdaq: ATXS), une entreprise biopharmaceutique spécialisée dans les maladies allergiques et immunologiques, a offert des options d'achat d'actions à trois nouveaux employés dans le cadre de son Plan d'Incitation en Actions 2022. Les options, totalisant 180.000 actions, ont été émises le 3 septembre 2024, avec un prix d'exercice de $11,46 par action, correspondant au prix de clôture à la date d'octroi.
Ces options s'acquitteront sur quatre ans, avec 25% acquises après un an et le reste acquérant mensuellement au cours des 36 mois suivants. Les concessions respectent la Règle de Cotation Nasdaq 5635(c)(4) pour les incitations matérielles destinées aux nouveaux employés. Ce plan est utilisé exclusivement pour la remise d'actions à des individus n'ayant pas été employés auparavant par Astria.
Astria Therapeutics (Nasdaq: ATXS), ein biopharmazeutisches Unternehmen, das sich auf allergische und immunologische Erkrankungen spezialisiert hat, hat Aktienoptionen an drei neue Mitarbeiter im Rahmen seines Inducement Stock Incentive Plans 2022 gewährt. Die Optionen, insgesamt 180.000 Aktien, wurden am 3. September 2024 ausgegeben, zu einem Ausübungspreis von $11,46 pro Aktie, was dem Schlusskurs am Gewährungsdatum entspricht.
Diese Optionen werden über vier Jahre erworben, wobei 25% nach einem Jahr und der Rest in den folgenden 36 Monaten monatlich erworben wird. Die Gewährungen entsprechen der Nasdaq-Listingregel 5635(c)(4) für Anreizinstrumente, die neuen Mitarbeitern gewährt werden. Dieser Plan wird ausschließlich für Aktienvergaben an Personen verwendet, die zuvor nicht bei Astria beschäftigt waren.
- Astria Therapeutics is attracting new talent with stock option incentives
- The company is expanding its workforce, potentially indicating growth
- Potential dilution of existing shareholders' equity due to new stock options
The options were granted as an inducement material to three employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904659494/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics
FAQ
How many stock options did Astria Therapeutics (ATXS) grant on September 3, 2024?
What is the exercise price of the stock options granted by Astria Therapeutics (ATXS)?
How do the stock options granted by Astria Therapeutics (ATXS) vest?
Under which plan did Astria Therapeutics (ATXS) grant these stock options?
